Answer
The most commonly reported adverse reactions in phase III clinical studies of riluzole in patients with ALS were asthenia, nausea and abnormal liver function tests.
Sources for this answer
- Riluzole 50 mg film-coated tabletsRanbaxy (UK) Limited a Sun Pharmaceutical Company · emc · SmPC §4.8 Undesirable effects · Version 8Document updated
Sources checked